{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T12:43:35Z","timestamp":1790772215705,"version":"4.1.0"},"reference-count":45,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,1,21]],"date-time":"2023-01-21T00:00:00Z","timestamp":1674259200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["HL081588"],"award-info":[{"award-number":["HL081588"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001602","name":"Science Foundation Ireland","doi-asserted-by":"publisher","award":["16\/SPP3303"],"award-info":[{"award-number":["16\/SPP3303"]}],"id":[{"id":"10.13039\/501100001602","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001602","name":"Science Foundation Ireland","doi-asserted-by":"publisher","award":["20\/FFP-A\/8952"],"award-info":[{"award-number":["20\/FFP-A\/8952"]}],"id":[{"id":"10.13039\/501100001602","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100006769","name":"Russian Science Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100006769","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["jthjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Thrombosis and Haemostasis"],"published-print":{"date-parts":[[2023,5]]},"DOI":"10.1016\/j.jtha.2023.01.013","type":"journal-article","created":{"date-parts":[[2023,1,20]],"date-time":"2023-01-20T12:31:05Z","timestamp":1674217865000},"page":"1123-1134","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"title":["Heterogeneity in the half-life of factor VIII concentrate in patients with hemophilia A is due to variability in the clearance of endogenous von Willebrand factor"],"prefix":"10.1016","volume":"21","author":[{"given":"Einas","family":"Elsheikh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michelle","family":"Lavin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lilian Antunes","family":"Heck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Niamh","family":"Larkin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brendan","family":"Mullaney","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dearbhla","family":"Doherty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Megan","family":"Kennedy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catriona","family":"Keenan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Guest","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian","family":"O'Mahony","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Judicael","family":"Fazavana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Padraic G.","family":"Fallon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roger J.S.","family":"Preston","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Gormley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin","family":"Ryan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Niamh M.","family":"O'Connell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evelyn","family":"Singleton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary","family":"Byrne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"McGowan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sheila","family":"Roche","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mairead","family":"Doyle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maeve P.","family":"Crowley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan I.","family":"O'Shea","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Birgit M.","family":"Reipert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jill M.","family":"Johnsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven W.","family":"Pipe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jorge","family":"Di Paola","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter L.","family":"Turecek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James S.","family":"O'Donnell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jtha.2023.01.013_bib1","doi-asserted-by":"crossref","first-page":"540","DOI":"10.7326\/M19-1208","article-title":"Data and Demographics Committee of the World Federation of Hemophilia. Establishing the prevalence and prevalence at birth of hemophilia in males: a meta-analytic approach using national registries","volume":"171","author":"Iorio","year":"2019","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.jtha.2023.01.013_bib2","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1056\/NEJMoa067659","article-title":"Prophylaxis versus episodic treatment to prevent joint disease in boys with severe hemophilia","volume":"357","author":"Manco-Johnson","year":"2007","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jtha.2023.01.013_bib3","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1111\/j.1365-2516.2009.02159.x","article-title":"Controversies regarding the prophylactic management of adults with severe haemophilia A","volume":"15","author":"Valentino","year":"2009","journal-title":"Haemophilia"},{"key":"10.1016\/j.jtha.2023.01.013_bib4","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1111\/hae.14078","article-title":"Biological mechanisms underlying inter-individual variation in factor VIII clearance in haemophilia","volume":"26","author":"Turecek","year":"2020","journal-title":"Haemophilia"},{"key":"10.1016\/j.jtha.2023.01.013_bib5","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1111\/j.1538-7836.2009.03703.x","article-title":"Factor VIII requirement to maintain a target plasma level in the prophylactic treatment of severe hemophilia A: influences of variance in pharmacokinetics and treatment regimens","volume":"8","author":"Collins","year":"2010","journal-title":"J\u00a0Thromb Haemost"},{"key":"10.1016\/j.jtha.2023.01.013_bib6","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1055\/s-0041-1723769","article-title":"Heterogeneity in bleeding tendency and arthropathy development in individuals with hemophilia","volume":"47","author":"Rehill","year":"2021","journal-title":"Semin Thromb Hemost"},{"key":"10.1016\/j.jtha.2023.01.013_bib7","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1111\/hae.13778","article-title":"Manco-Johnson MJ; Joint Outcome Study Group Investigators. Factor VIII prophylaxis effects outweigh other hemostasis contributors in predicting severe haemophilia A joint outcomes","volume":"25","author":"Warren","year":"2019","journal-title":"Haemophilia"},{"key":"10.1016\/j.jtha.2023.01.013_bib8","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1111\/j.1365-2516.2011.02539.x","article-title":"Clinical severity of haemophilia A: does the classification of the 1950s still stand?","volume":"17","author":"Den Uijl","year":"2011","journal-title":"Haemophilia"},{"key":"10.1016\/j.jtha.2023.01.013_bib9","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1007\/s00228-009-0676-x","article-title":"Pharmacokinetics and dose requirements of factor VIII over the age range 3-74 years: a population analysis based on 50 patients with long-term prophylactic treatment for haemophilia A","volume":"65","author":"Bjorkman","year":"2009","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1016\/j.jtha.2023.01.013_bib10","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1111\/j.1365-2141.1995.tb05325.x","article-title":"Inter-individual variation in half-life of infused recombinant factor VIII is related to pre-infusion von Willebrand factor antigen levels","volume":"91","author":"Fijnvandraat","year":"1995","journal-title":"Br J Haematol"},{"key":"10.1016\/j.jtha.2023.01.013_bib11","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1055\/s-0037-1613759","article-title":"The half-life of infused factor VIII is shorter in hemophiliac patients with blood group O than in those with blood group A","volume":"83","author":"Vlot","year":"2000","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.jtha.2023.01.013_bib12","first-page":"494","article-title":"Factor VIII half-life and clinical phenotype of severe hemophilia A","volume":"90","author":"Van Dijk","year":"2005","journal-title":"Haematologica"},{"key":"10.1016\/j.jtha.2023.01.013_bib13","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0006745","article-title":"Models for prediction of factor VIII half-life in severe haemophiliacs: distinct approaches for blood group O and non-O patients","volume":"4","author":"Fischer","year":"2009","journal-title":"PLoS One"},{"key":"10.1016\/j.jtha.2023.01.013_bib14","doi-asserted-by":"crossref","first-page":"1780","DOI":"10.4103\/0366-6999.233604","article-title":"Pharmacokinetic studies of factor VIII in Chinese boys with severe hemophilia a: a single-center study","volume":"131","author":"Chen","year":"2018","journal-title":"Chin Med J"},{"key":"10.1016\/j.jtha.2023.01.013_bib15","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1182\/blood.2019000190","article-title":"Genetic determinants of VWF clearance and FVIII binding modify FVIII pharmacokinetics in pediatric hemophilia A patients","volume":"134","author":"Swystun","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.jtha.2023.01.013_bib16","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1182\/blood-2011-07-360594","article-title":"Population pharmacokinetics of recombinant factor VIII: the relationships of pharmacokinetics to age and body weight","volume":"119","author":"Bjorkman","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.jtha.2023.01.013_bib17","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1111\/jth.15183","article-title":"Factor VIII pharmacokinetics associates with genetic modifiers of VWF and FVIII clearance in an adult hemophilia A population","volume":"19","author":"Ogiwara","year":"2021","journal-title":"J\u00a0Thromb Haemost"},{"key":"10.1016\/j.jtha.2023.01.013_bib18","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.3324\/haematol.2019.217133","article-title":"Relationship between factor VIII activity, bleeds and individual characteristics in severe hemophilia A patients","volume":"105","author":"Abrantes","year":"2020","journal-title":"Haematologica"},{"key":"10.1016\/j.jtha.2023.01.013_bib19","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1111\/j.1538-7836.2008.03270.x","article-title":"Break-through bleeding in relation to predicted factor VIII levels in patients receiving prophylactic treatment for severe hemophilia A","volume":"7","author":"Collins","year":"2009","journal-title":"J\u00a0Thromb Haemost"},{"key":"10.1016\/j.jtha.2023.01.013_bib20","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1111\/ejh.13763","article-title":"on behalf of the iPATH study group. Pain and functional disability amongst adults with moderate and severe haemophilia from the Irish personalised approach to the treatment of haemophilia (iPATH) study","volume":"108","author":"Kennedy","year":"2022","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.jtha.2023.01.013_bib21","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.thromres.2018.12.027","article-title":"Bayesian pharmacokinetic-guided prophylaxis with recombinant factor VIII in severe or moderate haemophilia A","volume":"174","author":"Megias-Vericat","year":"2019","journal-title":"Thromb Res"},{"key":"10.1016\/j.jtha.2023.01.013_bib22","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.thromres.2017.07.003","article-title":"PK-driven prophylaxis versus standard prophylaxis: when a tailored treatment may be a real and achievable cost-saving approach in children with severe hemophilia A","volume":"157","author":"Pasca","year":"2017","journal-title":"Thromb Res"},{"key":"10.1016\/j.jtha.2023.01.013_bib23","doi-asserted-by":"crossref","first-page":"1784","DOI":"10.1182\/bloodadvances.2018017418","article-title":"Significant gynecological bleeding in women with low von Willebrand factor levels","volume":"2","author":"Lavin","year":"2018","journal-title":"Blood Adv"},{"key":"10.1016\/j.jtha.2023.01.013_bib24","doi-asserted-by":"crossref","first-page":"1585","DOI":"10.1182\/blood-2018-09-874636","article-title":"Increased galactose expression and enhanced clearance in patients with low von Willebrand factor","volume":"133","author":"Aguila","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.jtha.2023.01.013_bib25","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1111\/jth.13294","article-title":"Aging and ABO blood type influence von Willebrand factor and factor VIII levels through interrelated mechanisms","volume":"14","author":"Albanez","year":"2016","journal-title":"J\u00a0Thromb Haemost"},{"key":"10.1016\/j.jtha.2023.01.013_bib26","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1182\/blood-2012-07-444877","article-title":"Distinct characteristics of antibody responses against factor VIII in healthy individuals and in different cohorts of hemophilia A patients","volume":"121","author":"Whelan","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.jtha.2023.01.013_bib27","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1182\/blood-2015-10-675512","article-title":"FVIII-binding IgG modulates FVIII half-life in patients with severe and moderate hemophilia A without inhibitors","volume":"128","author":"Hofbauer","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.jtha.2023.01.013_bib29","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1186\/s13059-016-0974-4","article-title":"The ensembl variant effect predictor","volume":"17","author":"McLaren","year":"2016","journal-title":"Genome Biol"},{"key":"10.1016\/j.jtha.2023.01.013_bib30","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1111\/hae.12592","article-title":"Parameters influencing FVIII pharmacokinetics in patients with severe and moderate haemophilia A","volume":"21","author":"Kepa","year":"2015","journal-title":"Haemophilia"},{"key":"10.1016\/j.jtha.2023.01.013_bib31","doi-asserted-by":"crossref","first-page":"2864","DOI":"10.1182\/blood.2020005843","article-title":"The relationship between ABO blood group, von Willebrand factor, and primary hemostasis","volume":"136","author":"Ward","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.jtha.2023.01.013_bib32","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1182\/blood.V94.1.179.413k18_179_185","article-title":"von Willebrand factor propeptide in vascular disorders: a tool to distinguish between acute and chronic endothelial cell perturbation","volume":"94","author":"van Mourik","year":"1999","journal-title":"Blood"},{"key":"10.1016\/j.jtha.2023.01.013_bib33","doi-asserted-by":"crossref","first-page":"1753","DOI":"10.1182\/blood-2015-04-512731","article-title":"von Willebrand factor propeptide: biology and clinical utility","volume":"126","author":"Haberichter","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.jtha.2023.01.013_bib34","doi-asserted-by":"crossref","first-page":"4979","DOI":"10.1182\/blood-2007-09-110940","article-title":"Identification of type 1 von Willebrand disease patients with reduced von Willebrand factor survival by assay of the VWF propeptide in the European study: molecular and clinical markers for the diagnosis and management of type 1 VWD (MCMDM-1VWD)","volume":"111","author":"Haberichter","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.jtha.2023.01.013_bib35","doi-asserted-by":"crossref","first-page":"2336","DOI":"10.1182\/blood-2012-09-455089","article-title":"VWF propeptide and ratios between VWF, VWF propeptide, and FVIII in the characterization of type 1 von Willebrand disease","volume":"121","author":"Eikenboom","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.jtha.2023.01.013_bib36","doi-asserted-by":"crossref","first-page":"3150","DOI":"10.1182\/blood.V85.11.3150.bloodjournal85113150","article-title":"The affinity and stoichiometry of binding of human factor VIII to von Willebrand factor","volume":"85","author":"Vlot","year":"1995","journal-title":"Blood"},{"key":"10.1016\/j.jtha.2023.01.013_bib37","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1111\/j.1365-2516.2009.02005.x","article-title":"Factor VIII and von Willebrand factor interaction: biological, clinical, and therapeutic importance","volume":"16","author":"Terraube","year":"2010","journal-title":"Haemophilia"},{"key":"10.1016\/j.jtha.2023.01.013_bib38","doi-asserted-by":"crossref","first-page":"147","DOI":"10.3324\/haematol.2012.066019","article-title":"A common ancestor more than 10,000 years old for patients with R854Q-related type 2N von Willebrand\u2019s disease in Italy","volume":"98","author":"Casonato","year":"2013","journal-title":"Haematologica"},{"key":"10.1016\/j.jtha.2023.01.013_bib39","first-page":"88","article-title":"Intranasal DDAVP induced increases in plasma von Willebrand factor alter the pharmacokinetics of high-purity factor VIII concentrates in severe haemophilia A patients","volume":"5","author":"Deitcher","year":"1999","journal-title":"Haemophilia"},{"key":"10.1016\/j.jtha.2023.01.013_bib40","doi-asserted-by":"crossref","first-page":"3540","DOI":"10.1182\/blood-2007-11-122945","article-title":"A\u00a0shorter von Willebrand factor survival in O blood group subjects explains how ABO determinants influence plasma von Willebrand factor","volume":"111","author":"Gallinaro","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.jtha.2023.01.013_bib41","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1111\/jth.14471","article-title":"von Willebrand factor sialylation\u2014a critical regulator of biological function","volume":"17","author":"Ward","year":"2019","journal-title":"J\u00a0Thromb Haemost"},{"key":"10.1016\/j.jtha.2023.01.013_bib42","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1111\/bjh.15565","article-title":"von Willebrand factor clearance\u2014biological mechanisms and clinical significance","volume":"183","author":"O'Sullivan","year":"2018","journal-title":"Br J Haematol"},{"key":"10.1016\/j.jtha.2023.01.013_bib43","doi-asserted-by":"crossref","first-page":"2007","DOI":"10.1182\/blood-2016-04-713289","article-title":"Life in the shadow of a dominant partner: the FVIII-VWF association and its clinical implications for hemophilia A","volume":"128","author":"Pipe","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.jtha.2023.01.013_bib44","doi-asserted-by":"crossref","first-page":"2344","DOI":"10.1182\/blood-2017-05-786699","article-title":"Novel insights into the clinical phenotype and pathophysiology underlying low VWF levels","volume":"130","author":"Lavin","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.jtha.2023.01.013_bib45","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1111\/jth.12586","article-title":"WiN study group. von Willebrand disease and aging: an evolving phenotype","volume":"12","author":"Sanders","year":"2014","journal-title":"J\u00a0Thromb Haemost"},{"key":"10.1016\/j.jtha.2023.01.013_bib46","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1111\/bjh.15277","article-title":"Comorbidities associated with higher von Willebrand factor (VWF) levels may explain the age-related increase of VWF in von Willebrand disease","volume":"182","author":"Atiq","year":"2018","journal-title":"Br J Haematol"}],"container-title":["Journal of Thrombosis and Haemostasis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1538783623000417?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1538783623000417?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T03:37:52Z","timestamp":1761536272000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1538783623000417"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5]]},"references-count":45,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2023,5]]}},"alternative-id":["S1538783623000417"],"URL":"https:\/\/doi.org\/10.1016\/j.jtha.2023.01.013","relation":{},"ISSN":["1538-7836"],"issn-type":[{"value":"1538-7836","type":"print"}],"subject":[],"published":{"date-parts":[[2023,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Heterogeneity in the half-life of factor VIII concentrate in patients with hemophilia A is due to variability in the clearance of endogenous von Willebrand factor","name":"articletitle","label":"Article Title"},{"value":"Journal of Thrombosis and Haemostasis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jtha.2023.01.013","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Authors. Published by Elsevier Inc. on behalf of International Society on Thrombosis and Haemostasis.","name":"copyright","label":"Copyright"}]}}